{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:53:11Z","timestamp":1790855591121,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.semarthrit.2024.152479","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:13:19Z","timestamp":1716552799000},"page":"152479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions"],"prefix":"10.1016","volume":"67","author":[{"given":"Ryunosuke","family":"Ohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-1603","authenticated-orcid":false,"given":"Akihiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152479_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100129","article-title":"Autoimmune rheumatic diseases: one or many diseases?","volume":"4","author":"Moutsopoulos","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5114\/reum.2015.50550","article-title":"Early diagnosis of rheumatic diseases: an evaluation of the present situation and proposed changes","volume":"53","author":"Kwiatkowska","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2022.881556","article-title":"Current status and future challenges in the treatment of Rheumatic diseases","volume":"2","author":"Soriano","year":"2022","journal-title":"Front Drug Safet Regulat"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0005","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0006","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0008","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0011","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T Cell therapy: a versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0012","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra S\u00e1nchez","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0016","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0017","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0018","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0019","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0020","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1631\/jzus.B1200057","article-title":"Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Lan","year":"2012","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0021","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0022","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0023","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"American J Transplantat"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0024","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0026","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0027","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0029","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0030","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0031","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0032","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0033","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-015-0532-1","article-title":"Role of Jo-1 in the Immunopathogenesis of the anti-synthetase syndrome","volume":"17","author":"Ascherman","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0034","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","article-title":"Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis","volume":"144","author":"Preu\u00dfe","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of Antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0036","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0037","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of Antisynthetase antibodies specificities on Antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0038","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0039","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12026-017-8926-y","article-title":"Pathogenesis of systemic sclerosis\u2014Current concept and emerging treatments","volume":"65","author":"Furue","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5114\/reum.2019.87619","article-title":"Systemic sclerosis \u2013 multidisciplinary disease: clinical features and treatment","volume":"57","author":"Sobolewski","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0041","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0042","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/art.41798","article-title":"B Cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis","volume":"73","author":"Numajiri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0044","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0045","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0046","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0047","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MOH.0000000000000098","article-title":"The role of neutrophils in causing antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"22","author":"Schreiber","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0048","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/annrheumdis-2021-221984","article-title":"CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis","volume":"81","author":"Rousselle","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0049","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.ajpath.2017.05.003","article-title":"Monocytes Promote crescent formation in anti-myeloperoxidase antibody\u2013induced glomerulonephritis","volume":"187","author":"Rousselle","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0050","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba4163","article-title":"Pathogen-induced tissue-resident memory TH17 (TRM17) cells amplify autoimmune kidney disease","volume":"5","author":"Krebs","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0051","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus Cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0052","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0053","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"New England J Med"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0054","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0055","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","article-title":"Anti-CCP antibodies: the past, the present and the future","volume":"7","author":"van Venrooij","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0056","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.autrev.2014.08.012","article-title":"Anti-citrullinated peptides as autoantigens in rheumatoid arthritis\u2014Relevance to treatment","volume":"13","author":"Sakkas","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0057","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.37839","article-title":"Presence and Role of Anti\u2013Citrullinated Protein Antibodies in Experimental Arthritis Models","volume":"65","author":"Cantaert","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755844","article-title":"Toward overcoming treatment failure in rheumatoid arthritis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0059","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for Rheumatoid Arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0061","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0062","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T Cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0064","article-title":"Tolerability of CAR T Cell therapy in Autoimmune disease","volume":"7","author":"Taubmann","year":"2023","journal-title":"Arthrit Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0065","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0066","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0067","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0068","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1631\/jzus.B2200256","article-title":"Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches","volume":"23","author":"Gu","year":"2022","journal-title":"J Zhejiang University-Sci B"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T Cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0071","doi-asserted-by":"crossref","first-page":"12366","DOI":"10.3390\/ijerph191912366","article-title":"Price and Prejudice? The value of chimeric antigen receptor (CAR) T-Cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3182791257","volume":"36","author":"Faster","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0073","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0074","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-Cell therapy by site of care among patients with relapsed or refractory large B-Cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/5727516","article-title":"Immunotherapy deriving from CAR-T cell treatment in Autoimmune diseases","volume":"2019","author":"Chen","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0077","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0078","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0079","volume":"3","author":"Charrot","year":"2019","journal-title":"Future Perspect Hemasphere"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8+ T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune cd4+ t cells in an antigen-specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0081","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immuno-Oncol Techn"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0082","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/CJI.0b013e3181ad762b","article-title":"Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes","volume":"32","author":"Nakazawa","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0083","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","article-title":"Redirecting specificity of T-Cell populations For CD19 using the sleeping beauty system","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0084","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41587-022-01418-8","article-title":"High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails","volume":"41","author":"Shy","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric antigen receptor based therapy as a potential approach in Autoimmune diseases: how close are we to the treatment?","volume":"11","author":"Sadeqi Nezhad","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0086","first-page":"179","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science (1979)"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0087","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41590-019-0442-x","article-title":"Functional reprogramming of regulatory T cells in the absence of Foxp3","volume":"20","author":"Charbonnier","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0088","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2013.11.004","article-title":"Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?","volume":"150","author":"Jethwa","year":"2014","journal-title":"Clinical Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0089","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0091","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T Cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mole Therapy"},{"key":"10.1016\/j.semarthrit.2024.152479_bib0092","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammat"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:48:14Z","timestamp":1720046894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":92,"alternative-id":["S0049017224001197"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152479","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152479"}}